Regarding all the talk of p values and death reduc

Regarding all the talk of p values and death reduction rates, Share holder equity, uplisting probabilities, trial not being halted ....

The high confidence is obvious, that Leronlimab will achieve an acceptable p value and thus, Statistical Significance on the Phase III s/c Primary Endpoint.

All of the discussion of
death rates expected
death reduction % expected,
how p value is calculated
power's effect upon p value
how many of the 87 deaths are in the LL group

Reading all of these comments and questions, may feed the doubt of a new investors of course. But for those that really understand enough of the science, and really believe in LL, well, we can also get stirred into concern, the main reason not being lack of confidence in LL, but hey, some here have a lot of money riding on the LL train/ride.

Also, I like some others here, enjoy the technical and math aspect of investing in a biotech stock, it's kind of fun. No fun to loose money for sure. So why not look at and discuss anticipated p values and the why and how. In this sense, we kind of "earn" any gains we are blessed with. With a lot of money invested, I'm always interested in any jewels of wisdom or discovery to boost my level of confidence toward that 100% unattainable goal.